Karaca Cetin, Soyer Ozlem M, Baran Bulent, Ormeci Asli C, Gokturk Suut, Aydin Esra, Evirgen Sami, Akyuz Filiz, Demir Kadir, Besisik Fatih, Kaymakoglu Sabahattin
Department of Gastroenterohepatology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.
Antivir Ther. 2013;18(4):561-6. doi: 10.3851/IMP2381. Epub 2012 Sep 14.
To determine the efficacy of pegylated interferon-α (PEG-IFN-α) therapy for 24 months in chronic delta hepatitis (CDH).
Patients with CDH who were treated by PEG-IFN-α2a or -2b for 24 months were included in the study. Demographic, biochemical and virological parameters were recorded at baseline and during follow-up. All included patients completed a treatment period of 24 months and at least a 6 month (range 6-60) follow-up period. Biochemical and virological response rates at end of treatment and end of follow-up were calculated, and predictors of sustained virological response (SVR) were analysed.
In total, 32 patients (22 males; mean age ± SD 42.7 ± 12 years) with CDH who were treated with PEG-IFN-α2a (180 µg) or -2b (1.5 µg/kg) once a week subcutaneously for 24 months were included in the study. All patients had compensated liver disease (25 [78%] were non-cirrhotic), increased transaminase levels and HDV RNA positivity at baseline. Genotypic analyses of HDV showed genotype I in all. Mean duration of follow-up was 19.5 months. At the end of treatment, virological response was achieved in 16 (50%) patients. SVR at the end of follow-up was achieved in 15 (47%) patients. A negative HDV RNA at 6 months of treatment was the only predictor of SVR (OR = 20; 95% CI 2, 195; P = 0.01).
PEG-IFN-α treatment achieved SVR in approximately half of the patients with CDH, and relapse rate was very low during the follow-up. Negativity of HDV RNA at 6 months may predict SVR in CDH.
确定聚乙二醇化干扰素-α（PEG-IFN-α）治疗慢性丁型肝炎（CDH）24个月的疗效。
纳入接受PEG-IFN-α2a或-2b治疗24个月的CDH患者。在基线和随访期间记录人口统计学、生化和病毒学参数。所有纳入患者均完成了24个月的治疗期和至少6个月（6 - 60个月）的随访期。计算治疗结束时和随访结束时的生化和病毒学应答率，并分析持续病毒学应答（SVR）的预测因素。
本研究共纳入32例CDH患者（22例男性；平均年龄±标准差42.7±12岁），他们接受皮下注射PEG-IFN-α2a（180μg）或-2b（1.5μg/kg），每周1次，共24个月。所有患者在基线时均有代偿性肝病（25例[78%]为非肝硬化）、转氨酶水平升高和HDV RNA阳性。HDV基因分型分析显示均为I型。平均随访时间为19.5个月。治疗结束时，16例（50%）患者实现病毒学应答。随访结束时，15例（47%）患者实现SVR。治疗6个月时HDV RNA阴性是SVR的唯一预测因素（OR = 20；95%CI 2，195；P = 0.01）。
PEG-IFN-α治疗使约一半的CDH患者实现SVR，随访期间复发率很低。治疗6个月时HDV RNA阴性可能预测CDH患者的SVR。
